Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS
Study Number: AFT-25
Study Summary:
This study looks at the risks and benefits of active surveillance (AS) compared to guideline concordant care (GCC) in the setting of a pragmatic prospective randomized trial for low risk DCIS. Our overarching hypothesis is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AS approach does not yield inferior cancer or quality of life outcomes compared to GCC.
Status: Open
Study Coordinator(s)
- Navigator Angie, 309-243-3613, aearles@illinoiscancercare.com
- Michelle, 309-243-3622, mmartin@illinoiscancercare.com
